Houston pharmaceutical company announces C-level changes

Houston-based Bellicum Pharmaceuticals Inc. (Nasdaq: BLCM), a pharmaceutical company focusing on the treatment of specific types of cancer, is shaking up its C-suite following the resignation of its COO.

Annemarie Moseley plans step down as the company’s COO and executive vice president of clinical development, effective July 31. She will remain a consultant to Bellicum through January.

“I would like to thank Annemarie for her many contributions to the success of Bellicum, particularly in establishing…

Houston pharmaceutical company announces C-level changes syndicated post


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s